Study: Open-label Phase III trial (IMpower010) Completely resected early-stage NSCLC s/p adjuvant platinum-based chemo Atezolizumab 1200 q21 x 1 yr vs. best supportive care Efficacy: Among pts with stage II-IIIA
Study: Double-blind, randomized Phase III trial (COSMIC-311) RAI-refractory differentiated thyroid cancer pts with prior lenvatinib or sorafenib Cabozantinib 60 mg daily vs. placebo Efficacy: ORR: 18% vs. 0% Median PFS:
Study: Double-blind, randomized Phase III trial (ClarIDHy) Advanced cholangiocarcinoma with IDH1 mutation, progressed after 1 or 2 lines of therapy Ivosidenib 500 mg daily (n=124) vs. placebo (n=61) Efficacy: Median
Study: Placebo controlled, randomized Phase III trial (KEYNOTE-522) Newly diagnosed, non-metastatic (T1cN1-2 or T2-4N0-2), triple-negative breast cancer CARBOplatin-PACLitaxel x 4 => AC/EC x 4 => Surgery => adjuvant Rx: With
Study: Open-label phase II trial (TALENT) Advanced pancreatic (panNET) or gastrointestinal (GI-NET), grade 1/2 neuroendocrine tumor progressed on a targeted agent (pancreatic) or somatostatic analog (GI) Lenvatinib 24 mg PO
Study: Randomized, double-blind phase III study (KEYNOTE-811) First-line treatment for metastatic her2-positive gastric or GEJ adenocarcinoma Chemotherapy + trastuzumab + pembrolizumab (n=133) vs. chemotherapy + trastuzumab + placebo (n=131) Chemotherapy:
Study: Randomized, double-blind, placebo controlled phase III (CheckMate 577) Resected stage II/III esophageal or gastroesophageal junction cancer (R0) who had received neoadjuvant chemoradiotherapy and NOT achieved pathological CR Adjuvant nivolumab
Study: Single-arm phase II study (BGJ398) Advanced/metastatic cholangiocarcinoma with FGFR2 fusions/rearrangements with progression on >= 1 line Infigratinib 125 mg PO daily (21/28 days) Efficacy: ORR: 23.1% [15.6%-32.2%] Median DoR:
Study: Single-arm phase II study (CHRYSALIS) Advanced/metastatic NSCLC (EGFR Exon20ins) second-line post-platinum chemo Amivantamab single agent Efficacy: ORR: 36% [25%-47%] Median DoR: 6.8 mos [5.0 mos – NR] Median PFS:
Study: Single-arm phase II study (CodeBreaK 100, phase II part) Locally advanced or metastatic k-ras G12C mutant non-small cell lung cancer, progressed on anti-PD-1/PD-L1 and/or platinum-based combination chemotherapy AND targeted
Study: Randomized phase III study (IKEMA) Relapsed/refractory multiple myeloma with >=2 prior lines including lenalidomide and a proteasome inhibitor Isatuximab + carfilzomib + dexamethasone (n=179) vs. carfilzomid + dexamethasone (n=123)
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.